Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center-Reference-Cited by-同舟云学术

Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Published:2020-08-25 Issue:11 Volume:95 Page:1324-1333
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Sesques Pierre¹²^ORCID,Ferrant Emmanuelle¹,Safar Violaine¹,Wallet Florent³,Tordo Jérémie⁴,Dhomps Anthony⁴,Karlin Lionel¹,Brisou Gabriel¹²,Vercasson Marlène¹,Hospital‐Gustem Carole¹,Schwiertz Vérane⁵,Ranchon Florence²⁵,Rioufol Catherine²⁵,Choquet Marion¹,Sujobert Pierre²⁶⁷^ORCID,Ghergus Dana¹,Bouafia Fadhela¹,Golfier Camille¹²,Lequeu Helène¹,Lazareth Anne¹,Novelli Silvana⁷^ORCID,Devic Perrine⁸,Traverse Glehen Alexandra²⁷⁹,Viel Sébastien²¹⁰¹¹,Venet Fabienne²¹²,Mialou Valérie¹³,Hequet Olivier¹³,Chauchet Adrien¹⁴,Arkam Yazid¹⁵,Nicolas‐Virelizier Emmanuelle¹⁶,Peyrade Frederic¹⁷,Cavalieri Doriane¹⁸,Ader Florence¹⁹,Ghesquières Hervé¹²⁷,Salles Gilles¹²⁷,Bachy Emmanuel¹²⁷

Affiliation:

1. Department of Hematology Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

2. Claude Bernard Lyon 1 University Lyon France

3. Department of Critical Care Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

4. Department of Nuclear Medicine Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

5. Department of Pharmacy Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

6. Department of Hematology Laboratory Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

7. Lyon Cancer Research Center INSERM U1052 and CNRS UMR5286 Lyon France

8. Department of Neurology Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

9. Department of Pathology Hospices Civils de Lyon, Lyon Sud Hospital Pierre‐Bénite France

10. Department of Biological Immunology Hospices Civils de Lyon, Lyon Sud Hospital Lyon France

11. International Center for Research in Infectious Diseases INSERM U1111 and CNRS UMR5308 Lyon France

12. Department of Clinical Immunology Hospices Civils de Lyon, Edouard Herriot Hospital Lyon France

13. Department of Biology and Therapy Etablissement Français du Sang Auvergne‐Rhône‐Alpes Decines‐Charpieu France

14. Department of Hematology Besançon University Hospital Besançon France

15. Department of Hematology Hopital Emile Muller Mulhouse France

16. Department of Hematology Centre Léon Bérard Lyon France

17. Department of Hematology Centre Antoine Lacassagne Nice France

18. Department of Hematology Clermont Ferrand University Hospital Clermont Ferrand France

19. Department of Infectious Disease Hospices Civils de Lyon, Croix Rousse Hospital Lyon France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25951

Reference25 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity

3. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

4. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

5. Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

3. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22

4. Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma;HemaSphere;2024-08

5. A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers;International Journal of Molecular Sciences;2024-06-15